WLan-led financing reaches a €25 million first closing, comprising €3 million in new capital and €22 million in shareholder convertible-bond conversions.

Samplix today announced financing led by WLanholding GmbH (“WLan”) to expand commercial adoption of Xdrop, its single-cell screening platform that helps researchers identify and recover cells producing antibodies with the desired biological function. The financing strengthens Samplix’s balance sheet and supports the commercial expansion of Xdrop for antibody discovery and biotherapeutic development.

All major shareholders participated in the first closing. The round remains open to additional investors, with a total financing target of €30 million.

Bringing function-first screening to antibody discovery: Samplix’s proprietary Xdrop platform addresses long-standing bottlenecks in antibody discovery by enabling high-throughput, function-first screening against challenging targets, including membrane-bound proteins, and complex assay formats such as reporter-based assays. The platform enables researchers to screen, identify and recover cells producing antibodies with the desired function, creating a direct link between antibody function, the antibody-secreting cell and the corresponding antibody sequence. This approach has the potential to accelerate the discovery of next-generation antibody-based therapeutics.

"This investment is a further validation of the value our Xdrop platform brings to the antibody discovery community," said Dr Henrik Pfundheller, CEO of Samplix. " We are now in a strong position to further scale our platform, deepen our partnerships with biopharma and academia, and continue pushing the boundaries of what's possible in single-cell workflows. This is an important milestone in our mission to make drug-discovery faster, simpler, and more reliable."

WLan's investment reflects the growing confidence in Samplix's technology and its potential to reshape how antibody discovery is performed at scale. As part of the investment, Dr Werner Lanthaler, former CEO of Evotec, will join Samplix's Board of Directors within the next year, working closely with the management team to guide the company's next phase of growth.

"We are excited to partner with Samplix at this pivotal stage of its growth," said Dr Lanthaler, Founder and Managing Director of WLan. "The team has built a differentiated single-cell technology platform that solves real, persistent challenges in drug discovery. We believe Samplix is well positioned to become a category leader, and we look forward to supporting the team as they scale their impact across the industry."

About Samplix (samplix.com)

Samplix provides droplet microfluidics technology for functional single-cell analysis in the biopharmaceutical sector. At the core of its offering is the Xdrop platform, which encapsulates living cells and assay components in millions of stable double-emulsion droplets that create controlled microenvironments for cell-cell and cell-molecule interactions. The droplets are compatible with standard flow cytometry and cell-sorting equipment, enabling high-throughput analysis and sorting of functional droplets. This allows researchers to identify and isolate rare antigen-specific antibody-secreting cells from primary samples, based on functional activity. Selected living cells can be recovered for downstream analysis and antibody sequence recovery, while preserving native heavy- and light-chain pairing. Beyond antibody discovery, Samplix's technology supports functional and genomic single-cell workflows across immunotherapy, cell line development, genome editing, and other life science applications, serving biopharmaceutical companies and academic research institutions worldwide. Functional and genomics data generated from single cells in volume are increasingly required to train advanced AI models.

About WLan (wlanholding.com)

WLanholding GmbH is a privately owned investment company focused on long‑term value creation across technology, healthcare, and industrial sectors. The firm combines strategic capital with operational expertise to support companies through critical growth phases, organizational scaling, and market expansion. With a disciplined investment approach and an emphasis on sustainable business models, WLanholding partners closely with management teams to accelerate innovation, strengthen competitive positioning, and drive measurable impact. The company maintains an active portfolio across Europe and the US.